Differentiation therapy of leukemia: 3 decades of development.
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
A characteristic feature of leukemia cells is a blockade of differentiation at a distinct stage in cellular maturation. In the 1970s and 1980s, studies demonstrating the capabilities of certain chemicals to induce differentiation of hematopoietic cell lines fostered the concept of treating leukemia by forcing malignant cells to undergo terminal differentiation instead of killing them through cytotoxicity. The first promising reports on this notion prompted a review article on this subject by us 25 years ago. In this review, we revisit this interesting field of study and report the progress achieved in the course of nearly 3 decades. The best proof of principle for differentiation therapy has been the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Attempts to emulate this success with other nuclear hormone ligands such as vitamin D compounds and PPARgamma agonists or different classes of substances such as hematopoietic cytokines or compounds affecting the epigenetic landscape have not been successful on a broad scale. However, a multitude of studies demonstrating partial progress and improvements and, finally, the new powerful possibilities of forward and reverse engineering of differentiation pathways by manipulation of transcription factors support the continued enthusiasm for differentiation therapy of leukemia in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibitors of HDAC are known to differentiate AML cells.40,45–47”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“inhibition of HDAC1 and HDAC2, chromatin-modifying enzyme components of the SIN3A and NURD corepressor families aberrantly recruited to Pu.1 in Runx1-deficient cells, also restored expression of epigenetically repressed differentiation genes and terminal maturation (38–41”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 204 · Cited by 348
Metadata
- Authors
- Nowak, D., Stewart, D., & Koeffler, H. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-04-16
- Volume
- 113
- Issue
- 16
- Pages
- 3655-3665
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2943835
- OpenAlex
- W2035576418
- Cited by
- 348
- References
- 204
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 11 · 2023: 29 · 2022: 10 · 2021: 19 · 2020: 31 · 2019: 21 · 2018: 25 · 2017: 32 · 2016: 20 · 2015: 20 · 2014: 23 · 2013: 19 · 2012: 21
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- differentiation therapy, leukemia, acute promyelocytic leukemia, all-trans retinoic acid, terminal differentiation, PPARγ agonists, hematopoietic growth factors, epigenetic modulation, transcription factors, hematopoietic differentiation
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Humans, Neoplasm Proteins, Transcription Factors, Leukemia, Promyelocytic, Acute, Epigenesis, Genetic, History, 20th Century, History, 21st Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differentiation therapy of leukemia: 3 decades of development. https://app.cochat.ai/papers/10.1182/blood-2009-01-198911
- The paper
- Nowak, D., Stewart, D., & Koeffler, H. P. (2009). Differentiation therapy of leukemia: 3 decades of development. Blood. https://doi.org/10.1182/blood-2009-01-198911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.